EU clears Abbott's blood test for ovarian cancer

01/16/2010 | Clinica (subscription required)

Abbott Laboratories has received EU's CE Mark approval for Architect HE4, a blood test designed to help determine whether pelvic masses are benign or cancerous. The company says its product, co-developed with Fujirebio Diagnostics, is the world's first automated HE4 diagnostic. Abbott also filed an application with the FDA seeking 510(k) clearance for the test.

View Full Article in:

Clinica (subscription required)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ